Cognition Therapeutics Reports Improved 2025 Loss, Strong Cash Runway, and Key Clinical Milestones for Zervimesine

summarizeSummary

Cognition Therapeutics reported an improved net loss for 2025 and a strong cash position extending its runway through Q2 2027, alongside significant clinical progress for its lead candidate zervimesine in DLB psychosis and Alzheimer's disease.

check_boxKey Events

• Full Year 2025 Financial Results

  The company reported a net loss of $(0.32) per basic and diluted share for the year ended December 31, 2025, an improvement compared to a net loss of $(0.86) per share in 2024.

• Strong Cash Position and Runway

  Cognition Therapeutics ended 2025 with approximately $37.0 million in cash, cash equivalents, and restricted cash equivalents, providing sufficient funding to support operations through the second quarter of 2027.

• Advancing DLB Psychosis Program

  The company plans to meet with the FDA Division of Psychiatry by mid-2026 to discuss the registrational plan for zervimesine (CT1812) for the treatment of psychosis associated with Dementia with Lewy Bodies (DLB), following strong Phase 2 data showing a 102% slowing of psychotic symptoms versus placebo.

• Alzheimer's Study Enrollment Completed

  Enrollment for the 545-patient Phase 2 'START' study in mild cognitive impairment (MCI) and early Alzheimer's disease was completed in December 2025, with topline results anticipated in 2027.

auto_awesomeAnalysis

This 8-K provides a comprehensive update on Cognition Therapeutics' financial health and critical clinical development programs. While the company reported a net loss for 2025, it represents a significant improvement year-over-year. More importantly for a clinical-stage biotech, the company has secured a strong cash position of $37.0 million, extending its operational runway through the second quarter of 2027. This financial stability is crucial for advancing its pipeline. The most impactful news is the significant progress in its lead candidate, zervimesine (CT1812). The company is actively moving towards registrational trials for DLB psychosis, an area with high unmet medical need, supported by compelling Phase 2 data. Additionally, the completion of enrollment for the large Phase 2 'START' study in Alzheimer's disease marks a key milestone, setting the stage for topline results in 2027. Investors should monitor the upcoming FDA meeting for the DLB program and the progress of the Alzheimer's study.